Source-grounded facts extracted from CONMED Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
John E. Gallagher was appointed as Executive Vice President, Chief Financial Officer at CONMED Corp.
“On June 17, 2026, CONMED Corporation (the “Company”) announced that John E. Gallagher has been appointed to serve as the Company’s Executive Vice President, Chief Financial Officer beginning July 15, 2026 (the “Effective Date”).”
CONMED Corp entered into Purchase Agreements with certain holders of its 2.25% Convertible Senior Notes due 2027 valued at approximately $645.2 million aggregate principal amount of Notes from the holders thereof for approx (effective 2026-06-03).
“On June 3, 2026, CONMED Corporation, a Delaware corporation (“ CONMED ”), entered into separate, privately negotiated purchase agreements (the “ Purchase Agreements ”) with certain holders of its 2.25% Convertible Senior Notes due 2027 (the “ Notes ”). Under the terms of the Purchase Agreements, the Company agreed to purchase approximately $645.2 million aggregate principal amount of Notes from the holders thereof for approximately $637.2 million in cash.”
CONMED Corp amended First Omnibus Amendment and Increased Facility Activation Notice with the several banks and other financial institutions party thereto, as lenders; and JPMorgan Chase Bank, N.A., as administrative agent valued at $450 million (effective 2026-05-27).
“On May 27, 2026, CONMED Corporation, a Delaware corporation (“ CONMED ”) entered into the First Omnibus Amendment and Increased Facility Activation Notice (the “ First Amendment ”), among CONMED and its subsidiary Linvatec Nederland B.V., a Netherlands private limited company ( besloten vennootschap ), as borrowers; certain of CONMED’s other subsidiaries, as guarantors; the several banks and other financial institutions party thereto, as lenders; and JPMorgan Chase Bank, N.A., as administrative agent (the “ Administrative Agent ”).”
CONMED Corp incurred credit facility of $450 million with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted term SOFR plus margin ranging from 1.125% to 2.25% per annum; base rate maturing June 10, 2030.
“CONMED entered into the First Amendment to, among other things, obtain commitments for incremental senior secured delayed draw term “a” loans available in U.S. dollars to CONMED in an aggregate principal amount equal to $450 million (the “ Term A-2 Loan Facility ”), which is available to be borrowed in a single drawing on or prior to June 14, 2026.”
CONMED Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2026 at the 2026-05-18 meeting.
“3. The ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2026 was approved. Shares For Against Abstain Broker Non-Votes 27,295,501 1,636,906 6,829 0”
CONMED Corp shareholders approved Advisory vote on the compensation of our named executive officers at the 2026-05-18 meeting.
“2. The advisory vote on the compensation of our named executive officers was approved. Shares For Against Abstain Broker Non-Votes 26,230,404 1,742,683 26,798 939,351”
CONMED Corp shareholders approved Election of seven directors at the 2026-05-18 meeting.
“At the Company’s annual meeting of stockholders held on May 18, 2026, stockholders voted on three proposals and the final voting results are set forth below. 1. The following table sets forth the seven persons elected to serve until the 2027 annual meeting of stockholders and until a respective successor has been duly elected and qualified, or until such director’s earlier termination of service. Shares Name For Withhold Broker Non-Votes Patrick J. Beyer 27,649,816 350,069 939,351 David Bronson 27,509,362 490,523 939,351 LaVerne H. Council 27,291,818 708,067 939,351 Charles M. Farkas 26,103,593 1,896,292 939,351 Mark Kaye 27,680,526 319,359 939,351 Kim Kelderman 27,663,316 336,569 939,351 Barbara J. Schwarzentraub 27,566,345 433,540 939,351”
CONMED Corp: Amended and restated bylaws to update advance notice provisions, including timeframe for stockholder notices (90 to 120 days before anniversary of prior annual meeting), director interview requirement, and ministerial changes (effective 2026-05-19).
“On May 19, 2026, the Board adopted and approved the amended and restated by-laws of the Company (the "By-laws") to, among other things, make updates to reflect developments in Delaware law and current market practice, update the Company's advance notice provisions regarding stockholder nominations of directors and submissions of proposals regarding other business, including to modify the permissible timeframe for receipt of stockholder notices to 90 to 120 days prior to the first anniversary of the date of the annual meeting of stockholders for the preceding year, require that, to be eligible to serve as a director, candidates must make themselves available to be interviewed by the Board (or any committee or other subset thereof) and make ministerial and conforming changes.”
Kimberly Lockwood was appointed as Interim Corporate Controller and Interim Principal Accounting Officer at CONMED Corp.
“On May 19, 2026, the Board appointed Kimberly Lockwood as Interim Corporate Controller and Interim Principal Accounting Officer of the Company effective June 1, 2026.”
Jeff Mirviss was appointed as Director at CONMED Corp.
“On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.”
Celine Martin was appointed as Director at CONMED Corp.
“On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.”
CONMED Corp reported FY 2026 results: EPS $4.30 to $4.45. Guidance reaffirmed.
“The Company now expects year-over-year organic constant currency revenue growth, which excludes gastroenterology product sales, of approximately 5.0% to 6.5% compared to the prior guidance range of 4.5% to 6.0%. Full-year 2026 reported revenue is now expected to be in the range of $1.350 billion to $1.375 billion, compared to prior guidance of $1.345 billion to $1.375 billion.”
CONMED Corp reported Q1 2026 results: EPS $0.89.
“Adjusted diluted net earnings per share (1) were $0.89, compared to adjusted diluted net earnings per share of $0.95 in the first quarter of 2025.”
Kimberly A. Lockwood changed role as Senior Director of Financial Reporting at CONMED Corp.
“Kimberly A. Lockwood, who was acting as Interim Corporate Controller, has been promoted to Senior Director of Financial Reporting.”
Todd W. Garner changed role as Principal Accounting Officer at CONMED Corp.
“and Todd W. Garner, Executive Vice President of Finance and Chief Financial Officer, ceased serving in the role of Principal Accounting Officer.”
Andrew Moller was appointed as Principal Accounting Officer at CONMED Corp.
“On April 1, 2025, Mr. Moller was appointed Principal Accounting Officer”
Mark Kaye was appointed as Director at CONMED Corp.
“On February 24, 2025, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Mark Kaye as a director effective immediately.”
Curt R. Hartman departed as Special Advisor at CONMED Corp.
“As of the Separation Date, Mr. Hartman’s service relationship with the Company will cease.”
Curt R. Hartman was appointed as Special Advisor at CONMED Corp.
“Commencing on March 3, 2025 (the 'Transition Date'), Mr. Hartman will serve as a Special Advisor”
Curt R. Hartman changed role as non-executive officer at CONMED Corp.
“Effective as of January 1, 2025, Mr. Hartman will transition into a non-executive officer role”
Curt R. Hartman changed role as Chair of the Board at CONMED Corp.
“effective as of October 31, 2024, Curt R. Hartman’s service as Chair of the Board will cease”
Todd W. Garner changed role as Principal Accounting Officer at CONMED Corp.
“Todd W. Garner, Executive Vice President of Finance and Chief Financial Officer, will assume the role of Principal Accounting Officer.”
Kimberly A. Lockwood was appointed as Interim Corporate Controller at CONMED Corp.
“Kimberly A. Lockwood, Director of Financial Reporting & Controls, will serve as Interim Corporate Controller, effective September 30, 2024.”
Eric B. Staves departed as Vice President, Corporate Controller at CONMED Corp.
“On September 16, 2024, Eric B. Staves, Vice President, Corporate Controller, informed CONMED Corporation (the “Company”) that, effective September 27, 2024, he plans to leave the Company to pursue an executive opportunity.”
Stanley W. (Bill) Peters was terminated as President, Advanced Surgical & Advanced Endoscopic Technologies at CONMED Corp.
“On August 14, 2024, CONMED Corporation (the “Company”) announced that the employment of Stanley W. (Bill) Peters, the Company’s President, Advanced Surgical & Advanced Endoscopic Technologies, will terminate on August 31, 2024.”
Eric B. Staves changed role as Vice President, Corporate Controller at CONMED Corp.
“On May 22, 2024, Eric B. Staves was promoted to Vice President, Corporate Controller, effective July 1, 2024.”
Terence M. Berge departed as Vice President, Corporate Controller at CONMED Corp.
“Terence M. Berge, Vice President, Corporate Controller, informed CONMED Corporation (the “Company”) that he plans to retire as of June 30, 2024.”
Heather L. Cohen changed role as Executive Vice President and Chief Human Resources and Legal Officer at CONMED Corp.
“Heather L. Cohen, Executive Vice President and Chief Human Resources and Legal Officer, has transitioned to a Special Advisor role with the Company commencing on April 20, 2024”
Pat Beyer changed role as Chief Operating Officer at CONMED Corp.
“Pat Beyer, President of International and Global Orthopedics, has been promoted to the newly created role of Chief Operating Officer of CONMED Corporation (the “Company”), effective on April 24, 2024.”
CONMED Corp reported first quarter ended March 31, 2024 results: revenue $312.3 million.
“Florida, April 24, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights · Sales of $312.3 million increased 5.7% year-over-year as reported and 5.9% in constant currency. · Domestic revenue increased 7.2% year-over-year. · International revenue increased 3.8% year-over-year”
CONMED Corp reported financial results for the fourth quarter and full-year ended December 31, 2023.
“On January 31, 2024, CONMED Corporation issued a press release announcing financial results for the fourth quarter ended December 31, 2023.”
CONMED Corp updated its the third quarter ended September 30, 2023 guidance (reaffirmed).
“On October 25, 2023, CONMED Corporation issued a press release announcing financial results for the third quarter ended September 30, 2023.”
CONMED Corp reported second quarter ended June 30, 2023 results: revenue $317.7 million, net income $13,732, EPS $0.43. Guidance raised.
“Florida, July 26, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights · Sales of $317.7 million increased 14.6% year over year as reported and 16.6% in constant currency. Acquisitions contributed approximately 400 basis points of growth. · Domestic revenue increased 17.1%”
CONMED Corp shareholders approved Amend Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Exculpation of Certain Officers at the 2023-05-24 meeting.
“Amend Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Exculpation of Certain Officers 22,637,046 5,595,512 11,617 833,681”
CONMED Corp shareholders approved Advisory vote on Frequency of Advisory Vote on Named Executive Officer Compensation at the 2023-05-24 meeting.
“Advisory vote on Frequency of Advisory Vote on Named Executive Officer Compensation 27,903,715 9,418 323,593 7,449 833,681”
CONMED Corp shareholders approved Advisory vote on Named Executive Officer Compensation at the 2023-05-24 meeting.
“Advisory vote on Named Executive Officer Compensation 26,472,625 1,750,517 21,033 833,681”
CONMED Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 at the 2023-05-24 meeting.
“Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 26,610,832 2,461,523 5,501 0”
CONMED Corp shareholders approved Election of nine directors to serve until the first annual meeting of shareholders following the end of fiscal year ending December 31, 2023. at the 2023-05-24 meeting.
“Item 5.07 Submission of Matters to a Vote of Security Holders. The Annual Meeting was held on May 24, 2023. Holders of CONMED common stock were entitled to elect nine directors. On all matters which came before the Annual Meeting, holders of CONMED common stock were entitled to one vote for each share held. Proxies for 29,077,857 of the 30,560,476 shares of CONMED common stock entitled to vote were received in connection with the Annual Meeting. The following table sets forth the names of the nine persons elected at the Annual Meeting to serve as directors until the first annual meeting of shareholders following the end of the Company’s fiscal year ending December 31, 2023 and the number of votes cast for, against or withheld with respect to each person. 1. Election of Directors Director Votes Received Votes Withheld Broker Non-Votes David Bronson 27,586,738 657,437 833,681 Brian Concannon 27,642,732 601,443 833,681 LaVerne Council 27,667,570 576,605 833,681 Charles Farkas 27,727,684 5”
CONMED Corp reported the full year 2023 results: revenue between $1.205 billion and $1.250 billion, EPS in the range of $3.30 to $3.50. Guidance raised.
“Based on the first quarter results, the Company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.205 billion and $1.250 billion, compared to its prior guidance of between $1.170 billion and $1.220 billion.”
CONMED Corp reported the first quarter ended March 31, 2023 results: revenue $295.5 million, EPS $0.06.
“Florida, April 26, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights · Sales of $295.5 million increased 21.9% year over year as reported and 25.1% in constant currency. Acquisitions contributed approximately 570 basis points of growth. · Domestic revenue increased 25.4%”
CONMED Corp reported the fourth quarter ended December 31, 2022 results: revenue $250.9 million, net income $26,584, EPS $0.86.
“December 31, 2022. Fourth Quarter 2022 Highlights · Fourth quarter 2022 sales significantly impacted by the implementation of new warehouse management software. · Sales of $250.9 million decreased 8.4% year over year as reported and 7.0% in constant currency. Acquisitions contributed approximately 460 basis points of growth. · Domestic revenue decreased 3.9% year”
CONMED Corp amended Third Amendment to Seventh Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at The Third Amendment revises the interest rate calculation mechanics to reflect the adoption of the T (effective 2022-12-20).
“On December 20, 2022, CONMED and its subsidiary Linvatec Nederland B.V. entered into the Third Amendment (the “ Third Amendment ”) to CONMED’s Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021 (the “ Base Credit Agreement ” and, as amended by the First Amendment, dated as of June 6, 2022 (the “ First Amendment ”), the Second Amendment, dated as of August 1, 2022 (the “ Second Amendment ”), and the Third Amendment, the “ Credit Agreement ”), among CONMED, the Foreign Subsidiary Borrowers (as defined therein) from time to time party thereto, the several banks and other financial institutions or entities from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.”
Heather Cohen was appointed as Executive Vice President and Chief Human Resources and Legal Officer at CONMED Corp.
“Heather Cohen will succeed Mr. Jonas in the role of Executive Vice President and Chief Human Resources and Legal Officer.”
Daniel S. Jonas changed role as Special Counsel & Corporate Secretary at CONMED Corp.
“Effective December 6, 2022 (the “Transition Date”), Daniel S. Jonas, the Executive Vice President, Legal Affairs, General Counsel & Secretary of CONMED Corporation (the “Company”), will transition from his current role and continue as a full-time employee of the Company through his planned retirement date of July 1, 2026”
John (Jed) E. Kennedy retired as Group Executive Vice President, Advanced Endoscopic Technologies, QA/RA, Distribution and Customer Service at CONMED Corp.
“On March 5, 2022, CONMED Corporation announced that John (Jed) E. Kennedy, the Company’s Group Executive Vice President, Advanced Endoscopic Technologies, QA/RA, Distribution and Customer Service plans to retire as of April 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.